期刊
CELLULAR & MOLECULAR BIOLOGY LETTERS
卷 26, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s11658-021-00282-9
关键词
Doxorubicin; Drug resistance; Cancer; Chemotherapy
Resistance to conventional chemotherapeutic agents like DOX is a major challenge in cancer therapy, necessitating the exploration of new treatment modalities. Long non-coding RNAs play critical roles in drug resistance in tumors, with many associated with DOX resistance. This review lays the groundwork for introducing an lncRNA panel marker to predict DOX response and clinical outcomes in cancer patients.
Resistance against conventional chemotherapeutic agents is one of the main reasons for tumor relapse and poor clinical outcomes in cancer patients. Various mechanisms are associated with drug resistance, including drug efflux, cell cycle, DNA repair and apoptosis. Doxorubicin (DOX) is a widely used first-line anti-cancer drug that functions as a DNA topoisomerase II inhibitor. However, DOX resistance has emerged as a large hurdle in efficient tumor therapy. Furthermore, despite its wide clinical application, DOX is a double-edged sword: it can damage normal tissues and affect the quality of patients' lives during and after treatment. It is essential to clarify the molecular basis of DOX resistance to support the development of novel therapeutic modalities with fewer and/or lower-impact side effects in cancer patients. Long non-coding RNAs (lncRNAs) have critical roles in the drug resistance of various tumors. In this review, we summarize the state of knowledge on all the lncRNAs associated with DOX resistance. The majority are involved in promoting DOX resistance. This review paves the way to introducing an lncRNA panel marker for the prediction of the DOX response and clinical outcomes for cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据